There are 2934 resources available
Patient perspective/expectations
Presenter: Regine Ihlen
Session: Beyond initial radical treatment of patients with lung cancer
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Thierry Berghmans
Session: Beyond initial radical treatment of patients with lung cancer
Resources:
Slides
Webcast
1691 - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Presenter: Benedetta Pellegrino
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
2339 - Interferon ɣ (IFN-ɣ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)
Presenter: Jason Luke
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
2801 - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
3661 - Long-term Outcomes from the Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets): Anti-PD1 Brain Collaboration (ABC)
Presenter: Georgina Long
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Proffered Paper – Melanoma and other skin tumours - Invited Discussant LBA66, LBA67 and 1310O
Presenter: Bartosz Chmielowski
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Slides
Webcast
2545 - 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
Presenter: James Larkin
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
2804 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: primary analysis from the phase 3 IMspire170 trial
Presenter: Ana Arance
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Proffered Paper – Melanoma and other skin tumours - Invited Discussant LBA68_PR, LBA69 and 1311O
Presenter: Ulrich Keilholz
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Slides
Webcast